Navigation Links
Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
Date:3/7/2013

SAN DIEGO, March 7, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $33.7 million and $89.7 million for the fourth quarter and full year of 2012, respectively. Net loss was $32.8 million, or $0.29 per share, and $117.1 million, or $1.03 per share, for the fourth quarter and full year, respectively. 

"It has been a little more than one year since the Sequenom Center for Molecular Medicine (SCMM) launched MaterniT21 PLUS™, the first non-invasive prenatal test (NIPT) in the United States that measures circulating cell-free nucleic acids in maternal blood for the detection of fetal aneuploidies.  During 2012, SCMM established itself as the leader in the NIPT field with the good acceptance of MaterniT21 PLUS by the medical community," said Harry Hixson, Jr., Ph.D., Chairman and CEO of Sequenom.  "SCMM and its licensees have also seen rapid acceptance of non-invasive prenatal testing in countries outside the United States."

Fourth Quarter 2012 Performance
Total revenues for the fourth quarter of 2012 increased to $33.7 million, 117% over revenues of $15.5 million for the comparable period in 2011.  Fourth quarter 2012 revenues from the genetic analysis operating segment were essentially flat year-over-year, while revenues from the SCMM diagnostics services operating segment grew to $21.1 million in the fourth quarter of 2012 up from $2.8 million in the prior year period.  Revenues from the SCMM diagnostics segment are recorded primarily on the cash basis.

Total cost of revenues increased to $21.4 million for the fourth quarter of 2012, compared to $9.3 million for the prior year period.  Cost of revenues increased due to the significant increase in the number of diagnostic tests performed, with accessions of 33,000 sampl
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
2. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation ... of directors has approved a quarterly dividend of $0.275 (27.5 ... is payable on August 1, 2014, to holders of record ... CVS Caremark is dedicated to helping people on ... company in the United States . Through ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) today announced its financial ... quarter of 2008, the Company reported a,net loss of $21.1 ... of,$25.7 million, or $(0.68) per share, for the same period ... were $1.8 million compared with,$0.1 million for the same period ...
... April 30 CureDM, Inc., a,biopharmaceutical company developing ... 1 and 2 diabetes, announces its,achievement of a ... CureDM has successfully stabilized HIP to improve its,bioavailability ... used in man may be as much as ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2008 Results 2Neurocrine Biosciences Reports First Quarter 2008 Results 3Neurocrine Biosciences Reports First Quarter 2008 Results 4Neurocrine Biosciences Reports First Quarter 2008 Results 5Neurocrine Biosciences Reports First Quarter 2008 Results 6Neurocrine Biosciences Reports First Quarter 2008 Results 7Neurocrine Biosciences Reports First Quarter 2008 Results 8CureDM's Diabetes Therapy Achieves Major Development Milestone 2
(Date:7/13/2014)... Fuel additives are chemicals, which are ... fuel, kerosene, and so on, in order to enhance ... the corrosion effects caused by fuels and improving the ... fuel, provide economies of scale in the long run, ... cost of the fuel products. , The various fuel ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
Breaking Medicine News(10 mins):Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... EPIDEMIC ABROADMENLO PARK, Calif., May 7 Two-thirds of ... government funding to improve health in developing countries, while ... spending too much on global health, according to a ... towards U.S. global health and development assistance. Levels ...
... better than no treatment at all, study shows , , ... essential for reducing the risk of heart disease and ... matter of debate. , Now, two new analyses attempt ... attacks, all antihypertensive drugs work, with the exception of ...
... million adultsor one fourth of the people in the ... and this undiagnosed population accounts for an estimated $18 ... a study in a recent issue of Population ... Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... of Illinois at Chicago has received nearly $1 million ... to study the benefits of green healthy housing. , ... and Reinvestment Act of 2009. , UIC researchers will ... move from distressed, unhealthy public housing into green, affordable, ...
... Results in New Compounded Medication Program GLEN BURNIE, ... largest practice-to-home delivery veterinary pharmacy today announced the ... than 1,200 pet owners from across the U.S.Key ... about having convenient services and options that help ...
... Pharma GmbH received an Orphan Drug Designation (ODD) by ... the EMEA for inhaled PARI Tobramycin 100 delivered via ... the second ODD designation that PARI Pharma has received ... first ODD was granted for PARI,s inhaled cyclosporine delivered ...
Cached Medicine News:Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 2Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 3Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 4Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 5Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 6Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 2Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 3Health News:UIC receives $1M HUD grant to study green healthy housing 2Health News:VetCentric Releases Findings of Pet Owner Survey 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 4
... The Genesis II* Total Knee System ... Now, far more is possible with less ... options, while fully addressing both clinical and ... components meet these design goals, giving surgeons ...
Cruciate retaining, posterior stabilized and constrained components....
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
...
Medicine Products: